Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors

被引：100
作者：
Kwekkeboom, Dik J. [1 ]
Krenning, Eric P. [1 ]
机构：
[1] Univ Med Ctr, Erasmus MC, Dept Nucl Med, NL-3015 CE Rotterdam, Netherlands
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2016年 / 30卷 / 01期
关键词：
Neuroendocrine tumor; Carcinoid; Radionuclide therapy; PRRT; Treatment; RADIOLABELED SOMATOSTATIN ANALOG; PHASE-I; RADIOPEPTIDE LU-177-OCTREOTATE; CARCINOID-SYNDROME; SALVAGE THERAPY; COMBINATION; TOXICITY; SURVIVAL; Y-90-DOTATOC; CAPECITABINE;
D O I：
10.1016/j.hoc.2015.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.
引用
收藏
页码：179 / +
页数：15
相关论文
共 53 条
  • [31] Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
    Raymond, Eric
    Dahan, Laetitia
    Raoul, Jean-Luc
    Bang, Yung-Jue
    Borbath, Ivan
    Lombard-Bohas, Catherine
    Valle, Juan
    Metrakos, Peter
    Smith, Denis
    Vinik, Aaron
    Chen, Jen-Shi
    Hoersch, Dieter
    Hammel, Pascal
    Wiedenmann, Bertram
    Van Cutsem, Eric
    Patyna, Shem
    Lu, Dongrui Ray
    Blanckmeister, Carolyn
    Chao, Richard
    Ruszniewski, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06) : 501 - 513
  • [32] Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
    Reubi, JC
    Schär, JC
    Waser, B
    Wenger, S
    Heppeler, A
    Schmitt, JS
    Mäcke, HR
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (03) : 273 - 282
  • [33] Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
    Reubi, JC
    Waser, B
    Schaer, JC
    Laissue, JA
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (07) : 836 - 846
  • [34] Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
    Rinke, Anja
    Mueller, Hans-Helge
    Schade-Brittinger, Carmen
    Klose, Klaus-Jochen
    Barth, Peter
    Wied, Matthias
    Mayer, Christina
    Aminossadati, Behnaz
    Pape, Ulrich-Frank
    Blaeker, Michael
    Harder, Jan
    Arnold, Christian
    Gress, Thomas
    Arnold, Rudolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4656 - 4663
  • [35] Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients
    Ruszniewski, P
    Ducreux, M
    Chayvialle, JA
    Blumberg, J
    Cloarec, D
    Michel, H
    Raymond, JM
    Dupas, JL
    Gouerou, H
    Jian, R
    Genestin, E
    Bernades, P
    Rougier, P
    [J]. GUT, 1996, 39 (02) : 279 - 283
  • [36] Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
    Sabet, Amir
    Haslerud, Torjan
    Pape, Ulrich-Frank
    Sabet, Amin
    Ahmadzadehfar, Hojjat
    Gruenwald, Frank
    Guhlke, Stefan
    Biersack, Hans-Juergen
    Ezziddin, Samer
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (02) : 205 - 210
  • [37] Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy
    Seregni, E.
    Maccauro, M.
    Chiesa, C.
    Mariani, L.
    Pascali, C.
    Mazzaferro, V.
    De Braud, F.
    Buzzoni, R.
    Milione, M.
    Lorenzoni, A.
    Bogni, A.
    Coliva, A.
    Lo Vullo, S.
    Bombardieri, E.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (02) : 223 - 230
  • [38] Seregni E, 2010, Q J NUCL MED MOL IM, V54, P84
  • [39] Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor
    Stoeltzing, Oliver
    Loss, Martin
    Huber, Elisabeth
    Gross, Volker
    Eilles, Christoph
    Mueller-Brand, Jan
    Schlitt, Hans J.
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2010, 395 (02) : 185 - 192
  • [40] [177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney
    Sward, Christina
    Bernhardt, Peter
    Ahlman, Hakan
    Wangberg, Bo
    Forssell-Aronsson, Eva
    Larsson, Maria
    Svensson, Johanna
    Rossi-Norrlund, Rauni
    Kolby, Lars
    [J]. WORLD JOURNAL OF SURGERY, 2010, 34 (06) : 1368 - 1372
123456